Background: The perioperative management of antiplatelet therapy in noncardiac surgery patients who have undergone previous percutaneous coronary intervention (PCI) remains a dilemma. Continuing dual antiplatelet therapy (DAPT) may carry a risk of bleeding, while stopping antiplatelet therapy may increase the risk of perioperative major adverse cardiovascular events (MACE). Methods: Occurrence of Bleeding and Thrombosis during Antiplatelet Therapy In Non-Cardiac Surgery (OBTAIN) was an international prospective multicentre cohort study of perioperative antiplatelet treatment, MACE, and serious bleeding in noncardiac surgery. The incidences of MACE and bleeding were compared in patients receiving DAPT, monotherapy, and no antiplatelet therapy before surgery. Unadjusted risk ratios were calculated taking monotherapy as the baseline. The adjusted risks of bleeding and MACE were compared in patients receiving monotherapy and DAPT using propensity score matching. Results: A total of 917 patients were recruited and 847 were eligible for inclusion. Ninety-six patients received no antiplatelet therapy, 526 received monotherapy with aspirin, and 225 received DAPT. Thirty-two patients suffered MACE and 22 had bleeding. The unadjusted risk ratio for MACE in patients receiving DAPT compared with monotherapy was 1.9 (0.93e3.88), P¼0.08. There was no difference in MACE between no antiplatelet treatment and monotherapy 1.03 (0.31e 3.46), P¼0.96. Bleeding was more frequent with DAPT 6.55 (2.3e17.96) P¼0.0002. In a propensity matched analysis of

the lnLAA and LD remain significantly different between C/NC (P<0.001 for all) regardless of the lung volume correction method. Conclusions: Real-world, non-contrast thoracic CT scans can provide reproducible QCT data. LAA and LD seem more reproducible when volume corrected using the PFT measured TLC than when using the predicted TLC and suggests the former better compensates for submaximal inspiration prior to image acquisition. Contrast infusion has predictable effects on QCT metrics decreasing LAA by 33% and increasing and LD by 21%. Volume correcting using the PFT measured TLC reduces the contrast effect on LAA to 25% and LD to 10%. If validated by other centres, these findings suggest the pool of observational QCT data could be vastly expanded at little dollar and no radiation cost. Background: A previous study evaluating the psychometric properties of the traditional EQ-5D in asthmatic patients showed a high ceiling effect (59% of patients with perfect health) questioning its usefulness in these patients. Therefore, the EuroQol Group developed a new EQ-5D version increasing the number of responses from 3 to 5 levels. This new version, the EQ-5D-5L, has never been tested in asthmatic patients. The aim of this study is to examine the distribution and construct validity of the new EQ-5D-5L in a European cohort of asthmatic adolescents and adults. Methods: A subgroup of 316 patients between 12-40 years included in the ASTROLAB cohort who completed EQ-5D-5L in the online questionnaire were analysed. It is a brief, multi-attribute, generic, preference-based health status measure consisting of five dimensions of health-five response options. The index value ranges from 1 (best health possible) to −0.594 (negative values indicate health states worse than death), where 0 is the value assigned to death. Index values were calculated using the preference values from the Rasch Model developed from EQ-5D-3L French.To examine the distribution of the index measures of central tendency, dispersion, ceiling and floor effect, and observed range were calculated. Construct validity was examined by their ability to differentiate between known groups defined by the Asthma Control Questionnaire (ACQ-5) by ANOVA. ACQ-5 measures the presence of asthma symptoms during the previous week in 7 Likert scale response options, with a score ranging from 0 to 6 (lower score better asthma control). Three groups of asthma control were defined according to tertiles: good (ACQ-5 <0.4), intermediate (ACQ-5 0.4-1.2) and bad (ACQ-5 >1.2). Results: Mean EQ-5D-5L index was 0.80 (SD=0.17). The observed range was from −0.03 to 1, floor and ceiling effects were 0% and 22.8%, respectively. Mean EQ-5D-5L index for patients with well-controlled asthma was 0.91 (95% CI, 0.89-0.93); 0.84 (95% CI, 0.81-0.87) for those with intermediate and 0.73 (95% CI, 0.69-0.78) for patients with poorly controlled asthma. The differences were statistically significant (P<0.001) and of great magnitude between the end groups. Most subjects reported 'no problems' in mobility...

No abstract